Switching tumor necrosis factor alpha inhibitors in HLA-B27-associated severe heel enthesitis.
Olivieri
Ignazio
I
San Carlo Hospital, Potenza, Italy. ignazioolivieri@tiscalinet.it
Scarano
Enrico
E
Padula
Angela
A
D'angelo
Salvatore
S
Cantini
Fabrizio
F
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D000068800:Etanercept; D036981:Fasciitis, Plantar / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D015796:HLA-B27 Antigen / Q000378:metabolism*; D006365:Heel / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D025241:Spondylarthritis / Q000150:complications; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015796:HLA-B27 Antigen; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept